Erratum: Adoptive Cell Therapy—Act 1: The Beginning


Get Permission

In the September 25, 2017, issue of The ASCO Post, page 1, the date of approval was cited incorrectly for the genetically engineered T-cell therapy tisagenlecleucel (Kymriah). The U.S. Food and Drug Administration approved tisagenlecleucel on August 30, 2017. The T-cell therapeutic is approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. The ASCO Post regrets this typographic error. ■
Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.